House oversight hearing of FDA approval programs may be held in the spring.
This article was originally published in The Gray Sheet
Executive Summary
HOUSE OVERSIGHT CHAIRMAN BARTON FAVORS "SYSTEMATIC" CHANGES AT FDA over third-party review as a means of improving the efficiency of the agency's device and drug premarket programs. Speaking at a Jan. 12 press conference in Washington, D.C., Rep. Joe Barton (R-Tex.) said he "would not be willing to privatize the FDA."